Using Smartphone Application After Liver Transplantation
NCT05854472 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2025-04-02
Summary
The aim of this randomized controlled clinical study was a study that could facilitate the management of immunosuppressive therapy, including information specific to liver transplant patients, to increase immunosuppressive medication adherence and quality of life, and reduce anxiety in the early period in patients who have to use lifelong immunosuppressive medication to prevent organ rejection after liver transplantation. The aim of this study is to develop a smartphone application and evaluate the effectiveness of the application.
Research Question: What is the effect of smartphone application use on immunosuppressive medication adherence, anxiety and quality of life in patients undergoing liver transplant?
Research Hypotheses
H11: There is a difference between medication adherence in patients who use and do not use smartphone applications after liver transplantation at the 3rd month after discharge.
H21: There is a difference between the anxiety levels of the patients who used and did not use smart phone applications after liver transplantation in the first month after discharge.
H31: There is a difference between the anxiety levels of the patients using and not using smart phone applications after liver transplantation at the 3rd month after discharge.
H41: There is a difference between the quality of life of patients using and not using a smart phone application after liver transplantation, at the first month after discharge.
H51: There is a difference between the quality of life of patients who use and do not use smart phone applications after liver transplantation at the 3rd month after discharge.
H61: There is a difference between immunosuppressive blood drug levels in the 1st month after discharge in patients who use and do not use smart phone applications after liver transplantation.
H71: There is a difference between the immunosuppressive blood drug levels in the 3rd month after the discharge of the patients who used and did not use the smart phone application after liver transplantation.
H81: There is a difference between the rejection rates of patients who use and do not use smartphone applications after liver transplantation, within the 3 months after hospital discharge.
H91: There is a difference between the rates of readmission within the 3 months after hospital discharge in patients who use and do not use smart phone applications after liver transplantation.
Researchers will compare the experimental and control groups to see if there is a difference between patients' adherence to medication, quality of life, and anxiety levels. The experimental group is going to use the smartphone application developed specifically for patients with liver transplantation for 3 months.
Conditions
- Liver Transplantation
Interventions
- OTHER
-
smartphone based application use
A smartphone application content will be developed to facilitate the use of immunosuppressive drugs by individuals with liver transplantation and to provide guidance to patients. The effect of smartphone application usage on immunosuppressive drug compliance, anxiety and quality of life in liver transplant patients will be evaluated.
Sponsors & Collaborators
-
The Scientific and Technological Research Council of Turkey
collaborator OTHER -
Saglik Bilimleri Universitesi
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-02-27
- Primary Completion
- 2024-02-26
- Completion
- 2024-02-26
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
NCT05613010 ·Status: RECRUITING ·Phase: NA
-
CNI-free "Bottom"-up Immunosuppression in Patients Undergoing Liver Transplantation
NCT01023542 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant
NCT03216447 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)
NCT06354179 ·Status: RECRUITING ·Phase: PHASE4
-
Immune Tolerance Induction After Liver Transplantation
NCT07269041 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Psychosocial Risks in Liver Transplant Recipients
NCT02826460 ·Status: COMPLETED
-
A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
NCT04587024 ·Status: COMPLETED ·Phase: NA
-
Adherence to Immunosuppressive Therapy Liver Transplant Recipients
NCT01959308 ·Status: UNKNOWN
-
The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation
NCT03147157 ·Status: UNKNOWN ·Phase: NA
-
Liver Transplantation With Tregs at MGH
NCT03577431 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
NCT00456235 ·Status: COMPLETED ·Phase: PHASE4
-
Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient
NCT03256864 ·Status: COMPLETED ·Phase: PHASE4
-
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
NCT00135694 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation
NCT00890253 ·Status: UNKNOWN ·Phase: PHASE2
-
Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation
NCT03500848 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant
NCT04104438 ·Status: COMPLETED ·Phase: PHASE4
-
Liver Transplantation With Tregs at UCSF
NCT03654040 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk
NCT04473924 ·Status: WITHDRAWN ·Phase: PHASE2
-
mDOT for Immunosuppressant Adherence in Adolescent Liver Transplant Recipients
NCT03781830 ·Status: WITHDRAWN ·Phase: NA
-
Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function
NCT04258423 ·Status: TERMINATED ·Phase: PHASE3
-
Generic Immunosuppressive Drugs After Lung Transplantation
NCT01889017 ·Status: UNKNOWN
-
A Conversion Study to Assess Safety and Efficacy of a MR4 Based Immunosuppressive Regimen in Stable Liver Recipients
NCT00384202 ·Status: COMPLETED ·Phase: PHASE3
-
Improving Medication-taking After Liver Transplant
NCT01960322 ·Status: COMPLETED ·Phase: PHASE1
-
Steroid Free Immunosuppression in Liver Transplantation
NCT00296244 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients
NCT03427008 ·Status: WITHDRAWN ·Phase: NA